Figuring out when to buy a stock isn’t difficult. There are any number of growth stories being crammed down your throat from every direction. As we always say, everyone tells you what stocks to buy, few tell you what not to buy. But that’s only half the battle. Figuring out when to sell a winning stock is the most difficult decision for most investors to make. If you’re fortunate enough to have an objective rule to determine when to sell, consider yourself lucky. That’s where our dividend growth investing strategy, Quantigence, excels. If a company stops increasing their dividend, they’re gone. Replace with one that will.
Tech investing is a bit trickier. Oh sure, we have a few rules in place. Trim above 10% weighting in our tech portfolio, sell if revenue growth stalls or thesis changes, but what about hype? Several times in the past we’ve sold on strong hype, gene editing being one of those examples. In looking at our portfolio’s performance this year, one company has performed abnormally well. No, not the guy in the leather jacket’s company. We’re talking about CrowdStrike (CRWD).
Cybercrime is Big Money
One notable investigative piece we produced was on an elite team of hacker hunters we visited in Moscow back when it was kosher to fraternize with Russian AI companies. Understanding that 90% of cybercrime is financially motivated by PhD (poor hungry determined) types means understanding that there’s a lot of money to be made in solu